Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies

Naomi E. Allen, Ruth C. Travis, Paul N. Appleby, Demetrius Albanes, Matt J Barnett, Amanda Black, H Bas Bueno-de-Mesquita, Mélanie Deschasaux, Pilar Galan, Gary E. Goodman, Phyllis J. Goodman, Marc J. Gunter, Markku Heliövaara, Kathy J Helzlsouer, Brian E. Henderson, Serge Hercberg, Paul Knekt, Laurence N. Kolonel, Christina Lasheras, Jakob LinseisenE. Jeffrey Metter, Marian L. Neuhouser, Anja Olsen, Maria Valeria Pala, Elizabeth A Platz, Harri Rissanen, Mary E Reid, Jeannette M Schenk, Meir J Stampfer, Pär Stattin, Catherine M Tangen, Mathilde Touvier, Antonia Trichopoulou, Piet A van den Brandt, Timothy J. Key, Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.

METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.

RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).

CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.

Original languageEnglish
JournalJournal of the National Cancer Institute
Volume108
Issue number11
DOIs
Publication statusPublished - Nov 2016

Fingerprint

Selenium
Prostatic Neoplasms
Prospective Studies
Nails
Odds Ratio
Confidence Intervals
Observational Studies
Logistic Models
Research Personnel

Keywords

  • Journal Article

Cite this

Allen, N. E., Travis, R. C., Appleby, P. N., Albanes, D., Barnett, M. J., Black, A., ... Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (2016). Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies. Journal of the National Cancer Institute, 108(11). https://doi.org/10.1093/jnci/djw153

Selenium and Prostate Cancer : Analysis of Individual Participant Data From Fifteen Prospective Studies. / Allen, Naomi E.; Travis, Ruth C.; Appleby, Paul N.; Albanes, Demetrius; Barnett, Matt J; Black, Amanda; Bueno-de-Mesquita, H Bas; Deschasaux, Mélanie; Galan, Pilar; Goodman, Gary E.; Goodman, Phyllis J.; Gunter, Marc J.; Heliövaara, Markku; Helzlsouer, Kathy J; Henderson, Brian E.; Hercberg, Serge; Knekt, Paul; Kolonel, Laurence N.; Lasheras, Christina; Linseisen, Jakob; Metter, E. Jeffrey; Neuhouser, Marian L.; Olsen, Anja; Pala, Maria Valeria; Platz, Elizabeth A; Rissanen, Harri; Reid, Mary E; Schenk, Jeannette M; Stampfer, Meir J; Stattin, Pär; Tangen, Catherine M; Touvier, Mathilde; Trichopoulou, Antonia; van den Brandt, Piet A; Key, Timothy J.; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.

In: Journal of the National Cancer Institute, Vol. 108, No. 11, 11.2016.

Research output: Contribution to journalArticle

Allen, NE, Travis, RC, Appleby, PN, Albanes, D, Barnett, MJ, Black, A, Bueno-de-Mesquita, HB, Deschasaux, M, Galan, P, Goodman, GE, Goodman, PJ, Gunter, MJ, Heliövaara, M, Helzlsouer, KJ, Henderson, BE, Hercberg, S, Knekt, P, Kolonel, LN, Lasheras, C, Linseisen, J, Metter, EJ, Neuhouser, ML, Olsen, A, Pala, MV, Platz, EA, Rissanen, H, Reid, ME, Schenk, JM, Stampfer, MJ, Stattin, P, Tangen, CM, Touvier, M, Trichopoulou, A, van den Brandt, PA, Key, TJ & Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group 2016, 'Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies', Journal of the National Cancer Institute, vol. 108, no. 11. https://doi.org/10.1093/jnci/djw153
Allen, Naomi E. ; Travis, Ruth C. ; Appleby, Paul N. ; Albanes, Demetrius ; Barnett, Matt J ; Black, Amanda ; Bueno-de-Mesquita, H Bas ; Deschasaux, Mélanie ; Galan, Pilar ; Goodman, Gary E. ; Goodman, Phyllis J. ; Gunter, Marc J. ; Heliövaara, Markku ; Helzlsouer, Kathy J ; Henderson, Brian E. ; Hercberg, Serge ; Knekt, Paul ; Kolonel, Laurence N. ; Lasheras, Christina ; Linseisen, Jakob ; Metter, E. Jeffrey ; Neuhouser, Marian L. ; Olsen, Anja ; Pala, Maria Valeria ; Platz, Elizabeth A ; Rissanen, Harri ; Reid, Mary E ; Schenk, Jeannette M ; Stampfer, Meir J ; Stattin, Pär ; Tangen, Catherine M ; Touvier, Mathilde ; Trichopoulou, Antonia ; van den Brandt, Piet A ; Key, Timothy J. ; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. / Selenium and Prostate Cancer : Analysis of Individual Participant Data From Fifteen Prospective Studies. In: Journal of the National Cancer Institute. 2016 ; Vol. 108, No. 11.
@article{e3e707f547b74520ad84480124b239aa,
title = "Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies",
abstract = "BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95{\%} confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95{\%} CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95{\%} CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95{\%} CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95{\%} CI = 0.11 to 0.31, Pheterogeneity = .08).CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.",
keywords = "Journal Article",
author = "Allen, {Naomi E.} and Travis, {Ruth C.} and Appleby, {Paul N.} and Demetrius Albanes and Barnett, {Matt J} and Amanda Black and Bueno-de-Mesquita, {H Bas} and M{\'e}lanie Deschasaux and Pilar Galan and Goodman, {Gary E.} and Goodman, {Phyllis J.} and Gunter, {Marc J.} and Markku Heli{\"o}vaara and Helzlsouer, {Kathy J} and Henderson, {Brian E.} and Serge Hercberg and Paul Knekt and Kolonel, {Laurence N.} and Christina Lasheras and Jakob Linseisen and Metter, {E. Jeffrey} and Neuhouser, {Marian L.} and Anja Olsen and Pala, {Maria Valeria} and Platz, {Elizabeth A} and Harri Rissanen and Reid, {Mary E} and Schenk, {Jeannette M} and Stampfer, {Meir J} and P{\"a}r Stattin and Tangen, {Catherine M} and Mathilde Touvier and Antonia Trichopoulou and {van den Brandt}, {Piet A} and Key, {Timothy J.} and {Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group}",
note = "{\circledC} The Author 2016. Published by Oxford University Press.",
year = "2016",
month = "11",
doi = "10.1093/jnci/djw153",
language = "English",
volume = "108",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Selenium and Prostate Cancer

T2 - Analysis of Individual Participant Data From Fifteen Prospective Studies

AU - Allen, Naomi E.

AU - Travis, Ruth C.

AU - Appleby, Paul N.

AU - Albanes, Demetrius

AU - Barnett, Matt J

AU - Black, Amanda

AU - Bueno-de-Mesquita, H Bas

AU - Deschasaux, Mélanie

AU - Galan, Pilar

AU - Goodman, Gary E.

AU - Goodman, Phyllis J.

AU - Gunter, Marc J.

AU - Heliövaara, Markku

AU - Helzlsouer, Kathy J

AU - Henderson, Brian E.

AU - Hercberg, Serge

AU - Knekt, Paul

AU - Kolonel, Laurence N.

AU - Lasheras, Christina

AU - Linseisen, Jakob

AU - Metter, E. Jeffrey

AU - Neuhouser, Marian L.

AU - Olsen, Anja

AU - Pala, Maria Valeria

AU - Platz, Elizabeth A

AU - Rissanen, Harri

AU - Reid, Mary E

AU - Schenk, Jeannette M

AU - Stampfer, Meir J

AU - Stattin, Pär

AU - Tangen, Catherine M

AU - Touvier, Mathilde

AU - Trichopoulou, Antonia

AU - van den Brandt, Piet A

AU - Key, Timothy J.

AU - Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group

N1 - © The Author 2016. Published by Oxford University Press.

PY - 2016/11

Y1 - 2016/11

N2 - BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.

AB - BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.

KW - Journal Article

U2 - 10.1093/jnci/djw153

DO - 10.1093/jnci/djw153

M3 - Article

C2 - 27385803

VL - 108

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -